Production (Stage)
Arcadia Biosciences, Inc.
RKDA
$4.28
$0.102.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -1.32% | -20.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.32% | -20.88% | |||
| Cost of Revenue | 6.07% | -38.94% | |||
| Gross Profit | -9.60% | 18.39% | |||
| SG&A Expenses | -34.29% | 17.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.57% | 1.33% | |||
| Operating Income | 42.59% | -20.74% | |||
| Income Before Tax | 164.51% | -240.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 164.38% | -241.54% | |||
| Earnings from Discontinued Operations | -- | 93.72% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 163.95% | -152.11% | |||
| EBIT | 42.59% | -20.74% | |||
| EBITDA | 42.63% | -20.02% | |||
| EPS Basic | 163.90% | -151.90% | |||
| Normalized Basic EPS | 121.89% | -227.54% | |||
| EPS Diluted | 163.81% | -151.90% | |||
| Normalized Diluted EPS | 121.89% | -227.54% | |||
| Average Basic Shares Outstanding | 0.08% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.09% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||